| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 366.45 KB | Adobe PDF |
Advisor(s)
Abstract(s)
Abstract Body:
PreClinical Imaging it is an each-day evolving field, getting more and more important at distinct
areas. The Biotechnology field is between those that taken the biggest benefit.
With so much interest, it is not surprising that investment consented on Research and
Development is also evolving at the same time that this specific branch of business into the
Imaging Industry is getting more and more attention and growing in importance.
Hybrid Imaging is also getting more and more interest in the last decade and actually there are
different vendors proposing interesting technical solutions, making things easier for one that
has the possibilities – and the knowledge about each will be the most adequate for the specific
purpose on each situation! – to choose one (or more) of those solutions.
This paper relates with the public presentation of images produced from the world first model
of a new pre-clinical imaging system, an new equipment that mixes Nuclear Medicine and MRI
Magnetic Resonance Imaging techniques, using as base the sub-millimeter Nano-SPECT (Single
Photon Emission Computed Tomography), so an high-level performance system – the world
reference, produced by MEDISO Company, in Hungary - from Nuclear Medicine and a new MRI
component, optimized for Neurosciences, but able to perform adequately on other critical
biological fields.
As practical example from the possibilities being introduced, images from mice, which are
being enrolled on a Neuroscience project, will be showed and will be discussed, but also will be
compared with other images being produced on other, actually more current, technical
solutions, in order to try to demonstrate the advantages and disadvantages of this specific new
approach.
Since this small – quick and unpretentious – comparison will be done, it is meant to make
possible understanding the place and the real possibilities of this equipment, which it is
expected to become available on the world market between the end of this year and the 1st
Quarter from next year.